Herpesvirus saimiri (HVS) has the ability to infect a variety of human cell lines and establish a persistent infection by virtue of episomal maintenance. Moreover, the viral episome provides sustained expression of a heterologous transgene. HVS-based vectors can also persist for a long term in tumor xenografts generated from HVS-infected human carcinoma cell lines. The viral episome remains latent within the xenograft allowing long-term transgene expression. These properties, in addition to its ability to incorporate large amounts of heterologous DNA, make HVS an attractive potential gene delivery vector. Here we report on the further evaluation of such HVS-based vectors. We demonstrate for the first time that HVS can efficiently infect solid tumor xenografts derived from a variety of human carcinoma cells via direct intratumoral injections. Furthermore, HVS can efficiently infect spheroid cultures, a three-dimensional cell culture system that closely resembles a tumor. Upon infection of both the tumor xenografts and spheroid cultures, HVS-based vectors can establish a persistent episomal infection within the tumor xenograft allowing expression of a heterologous transgene. These results suggest that HVS-based vectors may be suitable for cancer gene therapy applications.
H erpesvirus saimiri (HVS) is the prototype gamma-2 herpesvirus, or rhadinovirus. 1 HVS was originally isolated from its natural host, the squirrel monkey (Saimiri sciureus), in which it causes a persistent asymptomatic infection. However, experimental HVS infection of other New World primate species, such as tamarins (Saguinus spp), common marmosets (Callithrix jacchus) or owl monkeys (Aotus trivirgatus), can result in a number of lymphoproliferative diseases. 2, 3 Deletion of the transforming genes, STP and Tip, completely eliminates the oncogenic potential of the virus, 4 and all our vectors currently under development contain these deletions and as such are incapable of transforming any cell type.
The potential of HVS as a gene delivery vector was first highlighted in an early preclinical gene therapy trial. A nontransforming replication-competent HVS vector expressing the bovine growth hormone (bGH) was experimentally infected into New World primates. The results demonstrated that the primates produced circulating bGH and developed immunoglobulin G antibodies directed against bGH. The observation suggested that the latent persistence of the HVS genome could be utilized to replace gene products missing or defective in hereditary genetic disorders. 5 A number of studies have since been performed, using a range of HVS recombinant viruses, to determine whether HVS can infect and persist in human cells. The results demonstrated that the selectable viruses could infect and persist in an episomal form in a broad range of human cultured cell lines. The lines represented cells from the epithelium and connective tissues as well as from hematopoietic lineages. 6, 7 Viral episomes were still observed within infected cells long after selective pressure was removed. 6, 7 However, a number of these cell lines produced infectious virus. 6, 7 More recently, HVS recombinants have been produced expressing beta-galactosidase or enhanced green fluorescence protein (EGFP), and the neomycin resistance genes under the control of the IE CMV and SV40 promoters, respectively. [8] [9] [10] Analysis using these viruses, which can be grown to a high titer in the permissive owl monkey kidney (OMK) cell line, has demonstrated infection of a wide variety of human carcinoma cell lines at approaching 100% efficiency.
The virus DNA is able to establish a persistent episomal state within the human carcinoma cells, which segregates to the progeny upon cell division. 11, 12 The long-term presence of the HVS episome is believed not to affect cell growth, as the in vitro growth rates of uninfected human carcinoma cells and cells persistently infected with HVS-GFP showed no significant difference in the doubling time of the cell populations. This suggests that the maintenance of the HVS episome does not disrupt the growth machinery of human cancer cells in vitro.
HVS-based vectors may have several applications for gene therapy including delivery to cell types that are difficult to transfect, maintenance of gene expression throughout the cell cycle and during differentiation, simultaneous delivery and expression of several genes and regulation of gene expression using novel promoters. For example, the potential of HVS as a hematopoietic stem cell (HSC) vector has been highlighted by its ability to maintain heterologous gene expression throughout mouse embryonic stem cell differentiation in vitro. 13, 14 HVS-based vectors are able to infect totipotent mouse embryonic stem cells with high efficiency. The presence of the HVS genome was maintained and had no apparent effect on cell/colony morphology of the transduced mouse ES cells and no virus replication or production was observed. 13 Upon in vitro differentiation of these persistently infected mouse ES cells, the HVS genome is stably maintained into terminally differentiated macrophages. In addition, heterologous gene expression is maintained through differentiation. Moreover, the ability of HVS to infect and transform human T cells has led to the development of HVS as a potential episomal vector for adoptive immunotherapy of infectious and malignant diseases. [15] [16] [17] [18] To improve the biological safety of HVSbased vectors, the prodrug activating HSV thymidine kinase (HSV-TK) gene has been inserted into the HVS genome by homologous recombination. 15, 16 This allows the efficient elimination of both macaque and human T cells previously infected and transformed with the HVS-TK virus, in the presence of low concentrations of gancyclovir. The reinfusion of large numbers of autologous HVS-TK-transformed macaque T cells in the Old World primate was well tolerated and persisted for extended periods of time. 17 Moreover, addition of gancyclovir over the observation period of 12 months fully eliminated these transformed cells. Therefore, this HVS-based elimination method may form the basis of a novel method for the T-cell-dependent immunotherapy of resistant residual leukemia while avoiding the risk of uncontrolled graft versus host disease. [15] [16] [17] A prerequisite for the further development of HVS as a cancer gene delivery vector has been to elucidate whether HVS can maintain the properties of high infectivity rates and episomal persistence observed in vitro in an in vivo environment. To this end, tumor xenograft experiments were performed in nude mice comparing uninfected or HVS-infected human carcinoma cell lines. 12 Tumor xenografts were allowed to grow over a period of 3 months and animals were then analyzed for spread of the virus, persistence of the episome and expression of the GFP transgene. The results demonstrated that the HVSbased vector remained latent in the xenograft without spreading to other organs. Moreover, the long-term in vivo maintenance of the HVS genome, as a nonintegrated circular episome, provided efficient sustained expression of a heterologous transgene. Confirmation that the HVS episome had segregated to each of the tumor cells in the xenograft was also demonstrated by fluorescence microscopy using cross-sections of tumor xenografts. GFP expression was observed in over 90% of the cells throughout the HVS-GFP tumor xenografts. 12, 19 The long-term persistence of the HVS genome within the tumor xenograft indicates that upon cell division in vivo, the HVS episomal DNA was efficiently replicated and segregated to almost all daughter cells for at least a 3-month period.
However, these experiments utilized xenografts derived from carcinoma cells previously infected with HVS in vitro. Therefore, in this study, we have examined the ability of HVS to infect a solid tumor mass, using in vitro spheroid cultures and human tumor xenografts. Our data demonstrate that HVS can efficiently infect and develop a persistent episomal infection in a range of human tumor xenografts via intratumoral injections.
Materials and methods
Virus preparation and cell culture HVS-GFP 12 was propagated in OMK cells maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal calf serum (FCS). To purify large virus stocks suitable for in vivo analysis, roller bottle cultures of OMK cells were infected with HVS-GFP at a low multiplicity of infection (MOI; 0.1 PFU/ cell) and incubated at 371C for 4-5 days. Virus was pelleted, resuspended in Tris buffer (100 mM Tris-HCl (pH 8.0), 50 mM NaCl and 10 mM EDTA), layered onto a sucrose gradient (20-40%) and centrifuged at 19,000 rpm for 30 minutes. Purified infectious virus was harvested from the central fraction, pelleted and resuspended in phosphate-buffered saline (PBS). MiaPaCa (pancreatic), A673s (Ewing's sarcoma) and MCF7 (breast) cell lines were grown in DMEM (Invitrogen) supplemented with 10% (v/v) FCS. SW480 (colorectal) cells were grown in RPMI 1640 supplemented with 10% (v/v) FCS. SK-ES (Ewing's sarcoma) cell were grown in McCoys (Invitrogen) plus 2 mM glutamine (Sigma) and 15% FCS. All media contained penicillin (100 U/ml) and streptomycin (100 mg/ml) (Invitrogen).
Spheroid cultures and infections
Aggregation of A673 and SK-ES (Ewing's sarcoma) cells into small spheroids was initiated by seeding cell suspensions in DMEM or McCoys growth medium, respectively, into flasks coated with 1.4% agar (Invitrogen) for 3-4 days. After this, spheroids were transferred to spinner flasks, where they were maintained in growth media, with constant agitation (75 rpm) in a mixture of 95% air/5% CO 2 at 371C for up to 30 days. Media was replenished every 3 days by allowing the spheroids to settle in the bottom of the flask, aspirating 90-95% of the used media and replacing with fresh media. Spheroids (10-to 25-day cultures) were incubated with HVS-GFP at an MOI of 1, 2 or 5 in growth media at 371C for 1 hour. Media were removed and spheroids cultured for 24-120 hours under normal growth conditions. Spheroids were sampled from the cultures using a wide bore pipette, embedded in Cryo-M-bed (Bright Instruments, UK) and frozen in liquid nitrogen-cooled isopentane. Sections (3 mm) were cut onto glass slides, and stained with hematoxylin and eosin (H&E) for visualization by light microscopy or visualized under fluorescent light.
In vivo analysis
Female athymic Balb/C nude mice (8-10 weeks old; Harlan, UK) were maintained and handled in isolators under specific pathogen-free conditions. Mice were randomized into groups of four and wild-type human carcinoma cell line xenografts, SW480 (colorectal), MiaPaCa (pancreatic), A673s (Ewing's sarcoma) and MCF7 (breast), were induced by subcutaneous injection of 1 Â 10 7 cells in 50 ml of PBS into the right flank. Human tumor xenografts were allowed to grow to a size of 5 Â 5 mm. The tumor xenografts were then injected with 30 ml of 1 Â 10 8 PFU/ml of HVS-GFP or 30 ml of PBS at days 1, 3 and 5, at three different sites throughout the tumor. The tumor xenografts were then allowed to grow to a size of 10 Â 10 mm (usually 4 weeks postinjection) after which mice were killed. The tumor, brain, liver, lung, kidney, heart, spleen and colon were removed, snapfrozen in liquid nitrogen and stored at À801C prior to RNA, DNA and protein analysis.
PCR and RT-PCR analysis
Tissue samples were homogenized in 10 volumes of Trizol (Invitrogen) and DNA or RNA was then extracted as described by the manufacturer. The HVS open reading frame (ORF) 73, ORF 57, mGAPDH and hGAPDH were amplified as previously described. 12 
Gardella gel analysis
Tumor tissue was cut into pieces of approximately 1-2 mm 3 , incubated with a solution of 150 U/ml collagenase/ dispase (Sigma) in medium containing 10% FCS for 4 hours at 371C and then dissociated by passing through a 23-gauge needle. Episomal DNA molecules were detected using the Gardella gel technique. Horizontal gels were prepared in two steps. Initially, a 0.75% agarose gel in Tris-borate-EDTA buffer was poured. Once solidified, 5 cm of the gel was removed and replaced with 0.8% agarose containing 2% sodium dodecyl sulfate and 1 mg/ ml of self-digested pronase (Sigma). Tissue and cell pellets were resuspended in sample buffer (15% Ficoll and 0.01% bromophenol blue) and electrophoresed at 41C for 2 hours at 40 V and then 18 hours at 160 V. DNA was hybridized with a 32 P-radiolabelled random-primed probe specific for the KpnE fragment of the HVS genome, using the Megaprime kit (Amersham), as described by the manufacturer.
To obtain the required sensitivity to detect HVS episomes within host tissues, the Gardella gel was cut into horizontal slices after electrophoresis. Each slice was then analyzed for HVS genomes by PCR. Each lane of the gel was then cut into horizontal slices after electrophoresis and melted at 651C, and 5 ml was analyzed directly by PCR for HVS genomes. A single round of PCR was performed to amplify ORF 73 as previously described.
Fluorescence and photography
Excised tumor xenografts were photographed with a yellow Whatman 12 filter (Kodak) to eliminate contaminating blue light. Blue light was used at a wavelength of 488 nm to excite GFP (emission at 507 nm) and the camera film exposed for 2 minutes. Tumor specimens were embedded in Cryo-M-bed (Bright Instruments, UK), frozen on dry ice and stored at À801C. Frozen samples (10 mm) were sectioned using a Leica CM3050 cryostat and observed for GFP expression using a Zeiss Axiovert 135TV inverted fluorescence microscope with a Neofluar Â 40 oil immersion.
Results

HVS can infect and provide transgene expression in a spheroid tumor model
To investigate the ability of HVS to infect solid tumors, we initially analyzed its ability to infect spheroid cultures. The spheroid model is a three-dimensional (3D) cell culture system that more closely resembles a tumor in vivo than adherent monolayers. 20, 21 Therefore, it provides a powerful in vitro model system to evaluate the infection efficiency and maintenance of HVS in a solid 3D tumor cell mass. Spheroids were initiated by culture of cells of the Ewing's sarcoma family of tumors on agar for 3-4 days, and aggregates were then transferred to spinner culture flasks. In order to assess the ability of HVS to infect the tumor cell mass, spheroids were incubated with HVS-GFP at an MOI of 1, 2 or 5 and cultured for a further 24-120 hours. Cross-sections of tumor spheroids were then taken and analyzed by fluorescence microscopy. GFP expression was observed in the majority of the cells throughout the tumor spheroids (Fig 1) . In particular, widespread infection was observed throughout the highly viable proliferative cell mass, in contrast to the central necrotic area. Moreover, GFP expression was maintained in the spheroid tumor mass for 45 days after the initial infection (data not shown). These data demonstrate the ability of HVS-based vectors to infect efficiently cells in 3D spheroids and suggest that HVS can infect solid tumor mass.
Efficient infection of human tumor xenografts via direct intratumoral injections
We have previously shown that HVS-based vectors are capable of persisting in an in vivo environment. However, these experiments utilized cell lines previously infected and stably transduced with the virus vector. Therefore, we now wished to determine whether similar infection and persistence in a solid tumor mass could be achieved via a direct intratumoral injection. To this end, wild-type SW480 (colorectal), MiaPaCa (pancreatic), A673s (Ewing's sarcoma) or MCF7 (breast) carcinoma cells were used to induce tumor xenografts and allowed to grow to a size of approximately 5 mm Â 5 mm. Then three of the four mice were directly injected with 30 ml of 1 Â 10 8 PFU/ ml of sucrose gradient-purified HVS-GFP and a single mice was injected with PBS as a control. Virus was injection into three different sites of each tumor. Controls were injected with a similar amount of PBS. The injections were repeated at days 3 and 5. Tumor xenografts were then allowed to grow to a size of approximately 10 Â 10 mm, usually 2-4 weeks postinjection. DNA, RNA and protein were then extracted from the tumor, brain, heart, lungs, liver, kidney, spleen and colon of each animal for analysis.
To verify the presence of the HVS genome in the tumor xenografts and detect potential spread of the virus to other major organs as a result of the direct injections, PCR amplification was utilized. Specific amplification of the ORF 73, a gene latently expressed in human carcinoma cell lines, 11 was performed. In addition, as a suitable control, GAPDH DNA was detected in all samples, indicating that sufficient amounts of DNA had been extracted from each tissue. The HVS ORF 73, mGAPDH and hGAPDH were PCR amplified with the primers and conditions previously reported. 12 Viral DNA was readily detected in human tumor xenografts derived from SW480 and A673 carcinoma cell lines directly injected with HVS-GFP (Fig 2) . Similar results were observed for MiaPaCa and MCF7 xenografts (data not shown). These results demonstrate that HVS can infect a solid tumor mass via direct intratumoral injection. In addition, HVS genomes were amplified from the host mouse liver and spleen samples but were not detected in Herpesvirus saimiri-based gene delivery vector PG Smith et al any other host tissues (Fig 2) . As expected, viral DNA was not detected in control tumor xenografts injected with PBS (data not shown).
HVS can establish a latent infection in human tumor xenografts via direct intratumoral injections
We have previously demonstrated that HVS can persist in human carcinoma cell lines and tumor xenografts in a latent state. To determine whether HVS can establish a persistent infection in human tumor xenografts via a direct injection, RT-PCR amplification was performed using RNA isolated from the tumor and tissue samples. As a control, GAPDH expression was detected in all samples. The establishment of a persistent latent infection was indicated by the expression of the latently expressed ORF 73 transcript 11 in human tumor xenografts derived from SW480 and A673 carcinoma cell lines directly injected with HVS-GFP (Fig 3) . Similar results were observed for MiaPaCa and MCF7 xenografts (data not shown). This suggests that a persistent infection, indicated by latent ORF 73 gene expression, can be achieved with human tumor xenografts upon direct intratumoral injections, as previously described for carcinoma cell lines and stably transduced xenografts in vitro and in vivo.
12,19
Interestingly, ORF 73 RNA expression was also detected in the liver, but this transcript was absent in other host tissues (Fig 3a and b) . However, as shown in Figure 2 , viral DNA was present in the liver and spleen; therefore a more sensitive nested PCR assay was performed to determine if ORF 73 was present in other host organs (Fig 3c) . Nested PCR identified ORF 73 expression in both the liver and spleen, suggesting that the virus can infect and may establish a persistent infection in the liver and spleen.
RT-PCR analysis also identified ORF 57 expression, a lytically expressed gene, 22 in each tumor xenograft and in the liver (Fig 3a and b) . The more sensitive nested PCR assay also demonstrated ORF 57 expression in the spleen (Fig 3c) . This suggests that there may be limited lytic gene expression within the tumor xenografts and in the mouse liver and spleen from direct intratumoral injections. The presence of lytic gene expression is not surprising, as we have previously observed a very low level of spontaneous replication in stably transduced lung carcinoma cell lines and human tumor xenografts. 11, 12, 19 HVS is maintained as a circular episome in human tumor xenografts after direct intratumoral injections
We have previously shown that the HVS genome can persist as a circular episome in human carcinoma cell lines and stably transduced human tumor xenografts. 11, 12, 19 To verify the existence of HVS genomes in a circular, nonintegrated episomal form in human tumor xenografts after direct injection, viral DNA conformation was analyzed by Gardella gel electrophoresis and Southern blot analysis. [23] [24] [25] An HVS-transformed T-cell line from cottontop tamarin monkeys, 16, 26 which contains HVS as a circular nonintegrated episome, was also analyzed as a suitable control. The results show a band corresponding to episomal HVS DNA present in all human tumor xenografts directly injected with HVS-GFP that was not present in tumor xenografts injected with PBS (Fig 4a) . This result suggests that a persistent infection can be established after a direct injection of a human tumor xenograft where the HVS genome remains as a circular nonintegrated episome that is not incorporated into the host cell genome.
To verify the existence of HVS genomes in a circular, nonintegrated episomal form in the mouse liver and spleen, a more sensitive Gardella assay was utilized, namely a PCR modification of the Gardella gel technique. This method has previously been used to detect latent herpesvirus episomes in vivo. 24, 25 In contrast to analyzing the Gardella gel by Southern blotting, each lane of the gel is cut into horizontal slices after electrophoresis. Each slice was then analyzed for HVS genomes by PCR amplification of ORF 73. Gardella analysis was performed on the liver and spleen organs from the mouse bearing the SW480 tumor xenograft after 4 weeks postinfection. The results show a bands corresponding to episomal HVS DNA present in the tumor, liver and spleen (Fig 4b) . This result suggests that HVS-GFP can establish a persistent episomal infection, where the HVS genome remains as a circular nonintegrated episome that is not incorporated into the host cell genome, within the tumor and also in the mouse liver and spleen tissues. The HVS episome provides sustained transgene expression in human tumor xenografts via direct intratumoral injections
To determine whether HVS episomes allow sustained expression of a transgene after direct injection into human tumor xenografts, direct visualization of GFP was performed. To visualize the efficiency of HVS-GFP infection and analyze GFP expression within the human carcinoma xenografts, the tumors were exposed to light emitted at the excitation wavelength for GFP (488 nm) upon removal. The time of removal varied between 2 and 4 weeks due to the growth rates of each specific tumor xenografts. This analysis showed widespread GFP fluorescence in all tumor xenografts injected with HVS-GFP (Fig 5) , but not in the wt tumor xenografts injected with PBS (data not shown). Moreover, around the sites of injection large areas of the tumor expressed GFP intensely (indicated by arrows). This suggests that the HVS-GFP based vector can efficiently infect tumor xenografts via a direct intratumoral injection and establish a persistent latent episomal infection which can be maintained for at least 1 month of tumor xenograft growth.
To further analyze the efficiency of HVS infection and to determine whether the HVS episome has the ability to segregate to each of the tumor cells in the xenograft, cross-sections of tumor xenografts were taken and analyzed by fluorescence microscopy. GFP expression was observed in the majority (470%) of cells throughout the tumor xenografts (Fig 6) . This shows that the HVS genome can stably transduce and persist within the tumor xenograft and suggests that upon cell division in vivo, the HVS episomal DNA is efficiently replicated and segregates to daughter cells. These results confirm the ability of HVS-based vectors to efficiently infect tumor xenografts via direct intratumoral injections. Moreover, it suggests that upon infection the HVS vector can persist as a latent episome that can segregate in human carcinoma cells in vivo. Integrated and episomal DNAs were separated by electrophoresis, transferred to nitrocellulose and hybridized with a 32 P-radiolabelled random-primed probe specific for the KpnE fragment of the HVS genome. (b) Gardella gel and PCR analysis of HVS-infected SW480 cells, liver and spleen samples. Gardella gels were cut into horizontal slices after electrophoresis and melted at 651C, and 5 ml was analyzed directly by PCR for HVS genomes (ORF 73). 
Discussion
HVS is a large DNA virus thereby possessing the ability to package and deliver large amounts of heterologous DNA. We and others have previously demonstrated that HVS can infect a wide range of human cell lines and that the HVS genome persists in a latent episomal state that segregates to progeny upon cell division allowing longterm in vitro gene expression. [7] [8] [9] [10] [11] More recently, we demonstrated that the HVS genome can persist in human tumor xenografts derived from ex vivo HVS-infected human carcinoma cells. 12, 19 Our previous work has demonstrated that HVS-based vectors (expressing GFP) persisted as nonintegrated episomes in vivo, and provided long-term transgene expression with no evidence of promoter silencing, viral spread or cytopathic effects. In this study, we examined the ability of HVS-based gene therapy vectors to infect cells in a spheroid tumor model and in established human tumor xenografts in nude mice.
The multicellular tumor spheroid model is a 3D cell culture model that represents an organizational structure of tumor cells that more closely resembles in vivo tumor properties compared to the monolayer culture system. 20, 21 Ewing's sarcoma spheroids have an outer (100 mM) highly proliferative viable cell layer and an inner necrotic center. Following incubation of Ewing's sarcoma cell spheroids with HVS at low MOIs, we observed widespread infection of tumor cells throughout the viable highly proliferative cell mass, whereas the central necrotic area did not express GFP (Fig 1) . This suggests that the virus is able to pass through the extracellular space between the cells of the spheroid and expression is cell associated. Although we did not assess the establishment of a latent state within the cells, we have previously demonstrated that HVS can persist in a range of Ewing's sarcoma cell lines.
Although the spheroid model provides excellent evidence that HVS is capable of infecting 3D tumor structures, to prove that HVS can infect solid tumor masses we tested its ability to infect human tumor xenografts in nude mice. Tumor xenografts of SW480 (colorectal), MiaPaCa (pancreatic), A673s (Ewing's sarcoma) and MCF7 (breast) cells were generated and HVS-GFP was injected directly into the tumor xenografts and left to grow for a further 2-4 weeks. By PCR analysis, we could detect viral DNA present in all human tumor xenografts injected with HVS-GFP. Furthermore, it was demonstrated that HVS could establish a latent infection in tumor xenografts (Fig 3) . ORF 73 gene expression is required for latent episomal maintenance of HVS in cells in vitro through interaction with host mitotic chromosomes, 27 and the presence of ORF 73 gene expression in infected tumors showed that the virus had entered cells and established a latent state. 11 Analysis of tumor xenografts also showed that the viral genome was maintained as an episome that did not integrate into the genome of injected tumors (Fig 4) , adding further support to the use of HVS as a gene therapy vector. This minimizes the possibility of the vector causing insertional mutagenesis due to the integration of the host genome, a problem that has hampered the use of retroviral gene therapy systems. 28 Although ORF 73 expression in the tumor xenografts shows that the HVS genome is persisting in a latent state, this does not show whether transgene expression is occurring. To test that the latently infected HVS episome allowed transgene expression in infected tumors, we showed widespread GFP expression in the tumor xenografts by direct photography under UV light ( Figs  5 and 6 ). Cross-sections of tumor xenografts revealed that the most intense areas of GFP expression occurred closest to the site of injection, suggesting that the physical distribution explains the spread of the virus, rather than a limited replication or spread through the interstitial spaces. Although, it appears that HVS infection can occur at sites distant from injection in the tumors, it is unclear at this point whether this is due to the production Figure 6 Efficient transfer of the HVS episome after direct injection allows sustained transgene expression. To examine the amount of GFP expressed throughout the injected tumors, SW480 HVS-GFP-(i þ ii), A673 HVS-GFP-(iii þ iv) and mock-infected (v þ vi) tumor xenograft cross-sections were analyzed under normal light (i þ iii þ v) and light emitted at the excitation wavelength for GFP (ii þ iv þ vi). The results show the sections of the fully excised tumor at 1 month postinjection for (i, iii, iv) and 2 weeks postinjection for (ii). The analysis was repeated for each injected mouse, and similar fluorescence levels were observed for each mouse.
of infectious virus, the injected virus passing through the extracellular space or entering the vasculature. Hence, we have shown that HVS-GFP injected directly into human tumor xenografts can infect cells and the resultant latent episome allows expression of a transgene in vivo for up to 1 month postinjection. One consideration, however, is that in this analysis we cannot distinguish whether the ORF 73-expressing and GFP-expressing cells are the same or two distinct populations. It may be the case that GFP expression in only in those cells undergoing lytic expression. However, we believe that this is unlikely, as previous analysis of HVS-containing tumor xenografts has shown that ORF 73 expression coincides with GFP expression. 12 It will also be of interest to determine whether similar results of persistence and long-term expression are observed in immunocompetent animal models.
Previous in vitro studies detected lytic gene expression in stably transduced lung carcinoma cell lines. 11 More recently, we also detected expression of the lytic gene, ORF 57, in human tumor xenografts derived from infected SW480 colon carcinoma cells. However, we were unable to confirm whether viable infectious virus was produced in these tumor xenografts. 12 In this study, RT-PCR analysis revealed the presence of ORF 57 lytic gene expression in the tumors of host mice that were injected with HVS-GFP (Fig 3) . In addition we could detect ORF 57 gene expression in the liver and spleen of injected mice. At present, it is unclear whether the viral particles detected in the liver and spleen are a result of the production of lytic virus in vivo entering the vasculature or due to virus entering the circulatory system of tumors following direct injection. It is well characterized that the vasculature of tumors is leaky to macromolecules, 29, 30 and so it is not unreasonable to suggest that virus injected into the tumor leaks into the vasculature and spreads to the liver and spleen. Furthermore, depending on the point of injection, virus may have been directly injected into a blood vessel within the tumor resulting in some virus entering the circulatory system. Further studies are required to determine whether the detected lytic gene expression results in the production of infectious virus and whether this virus spreads in mice. However, the observation that the virus spreads to the liver in all cases suggests that the virus has a natural tropism for the liver. This is further supported by preliminary data demonstrating that HVS can infect hepatocarcinoma and liver stellate cells with high efficiency (unpublished observations). We are also currently developing a replicationdisabled HVS-based vector through deletion of the identified genes responsible for initiation of lytic gene expression, ORF 50 and ORF 57. [31] [32] [33] In addition, further studies examining localization of HVS following intravenous injection into nude mice are currently underway using noninvasive imaging techniques.
HVS has an array of desirable features required of a gene delivery vector. It has the ability to accommodate large amounts of heterologous DNA, can infect a wide range of human cell types and avoids problems with chromosomal integration through maintenance of the genome as a high copy number episome. We have now shown that HVS can infect solid tumors in vivo to a high efficiency and allows long-term gene expression following infection of selected tissues. This latest feature has broad implications for the therapeutic use of HVS, such as the efficient delivery of suicide or tumor suppressor genes to treat tumors. Moreover, the long-term persistence of the vector may be useful for the enhanced expression of RNAi and ribozyme constructs for the treatment of cancer. For example, the EWS-FLI1 chimeric oncogene, which results from a chromosomal translocation associated with Ewing's sarcoma, 34, 35 is an ideal target for RNAi-based applications in solid tumors. 36 In addition, the establishment of a persistent latent infection in the liver suggests that HVS-based vectors may have potential for the delivery of therapeutic genes for treatment of inherited and acquired liver diseases. 37 However, before these advantageous qualities can be realized, further development and analysis of vector properties is necessitated. Primarily, a replication-disabled vector should avoid dissemination of virus to unwanted tissues, and also the incorporation of a suicide gene for active elimination of the vector would allow for the control of any undesirable effects that may arise. Further studies are currently underway to address these issues.
